LUCD: the cashflow

MyFinsight

For the quarter ending 2025-09-30, LUCD had $16,209K increase in cash & cash equivalents over the period.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Debt extinguishment loss - senior secured convertible note	-	0
Net loss attributable to lucid diagnostics inc	-10,397	-31,347
Depreciation and amortization expense	220	443
Stock-based compensation - lucid diagnostics inc. 2018 equity plan	1,135	2,092
Stock-based compensation - pavmed inc. 2014 equity plan	17	82
Change in fair value - senior secured convertible note	-2,341	7,638
Equity issuance cost extinguishment	1,078	-
Amortization of common stock payment for vendor service agreement	87	147
Accounts receivable	177	328
Prepaid expenses and other current assets	283	942
Accounts payable	-82	-408
Accrued expenses and other current liabilities	-146	-407
Due to pavmed inc. - operating expenses, employee related costs, msa fee	-4	16
Net cash flows used in operating activities	-10,893	-23,014
Purchase of equipment	28	118
Net cash flows used in investing activities	-28	-118
Proceeds issue of common stock - registered direct offering, net of fees	0	14,935
Proceeds issue of common stock - confidentially marketed public offering, net of fees	26,997	16,174
Proceeds issue of preferred stock	-	0
Proceeds issue of senior secured convertible notes	0	360
Proceeds issue of common stock at-the-market facility	0	274
Proceeds exercise of stock options	2	13
Proceeds issue common stock employee stock purchase plan	131	141
Net cash flows provided by financing activities	27,130	31,897
Net increase in cash	16,209	8,765
Cash and cash equivalents at beginning of period	22,358	-
Cash and cash equivalents at end of period	47,332	-

Unit: Thousand (K) dollars